Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for patients with the 2019 coronavirus (COVID-19). However, little is known about their effectiveness in older adults and those at high risk of disease progression. This retrospective single-center observatio...

Full description

Bibliographic Details
Main Authors: Yoshikazu Mutoh, Takumi Umemura, Takeshi Nishikawa, Kaho Kondo, Yuta Nishina, Kazuaki Soejima, Yoichiro Noguchi, Tomohiro Bando, Sho Ota, Tatsuki Shimahara, Shuko Hirota, Satoshi Hagimoto, Reoto Takei, Jun Fukihara, Hajime Sasano, Yasuhiko Yamano, Toshiki Yokoyama, Kensuke Kataoka, Toshiaki Matsuda, Tomoki Kimura, Toshihiko Ichihara, Yasuhiro Kondoh
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Viruses
Subjects:
COVID-19
molnupiravir
nirmatrelvir/ritonavir
hospitalization
adverse event
older adults
Online Access:https://www.mdpi.com/1999-4915/15/3/811

Internet

https://www.mdpi.com/1999-4915/15/3/811

Similar Items